New Zealand In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Introduction

GlobalData’s new report, “New Zealand In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the New Zealand In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
- 2010 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the New Zealand In Vitro Diagnosticsmarket.
- Key players covered include F. Hoffmann-La Roche Ltd., Sysmex Corporation, Abbott Laboratories, Beckman Coulter, Inc., Siemens Healthcare, Becton, Dickinson and Company and others.

Highlights

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the New Zealand In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Report Highlights
F. Hoffmann-La Roche Ltd.
Sysmex Corporation
Abbott Laboratories
Beckman Coulter, Inc.
Siemens Healthcare
Becton, Dickinson and Company
Ortho-Clinical Diagnostics Inc.
Bio-Rad Laboratories, Inc.
bioMerieux S.A.
Alere Inc.
Qiagen N.V.
DiaSorin S.p.A
Life Technologies Corporation
HORIBA, Ltd.
Gen-Probe Incorporated
Danaher Corporation
Grifols, S.A.
Phadia AB
Thermo Fisher Scientific Inc.
DIAGNOSTICA STAGO, Inc.
PerkinElmer, Inc.
[Studien Infos ausblenden]

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 11
2 Introduction 14
2.1 What is This Report About? 14
3 In Vitro Diagnostics In New Zealand 15
3.1 In Vitro Diagnostics, Market Segmentation 15
3.2 In Vitro Diagnostics, New Zealand, Overall Revenue ($m), USD Actual, 2003-2017 16
3.3 In Vitro Diagnostics Market, New Zealand, Revenue Mix ($m), 2010 18
3.4 In Vitro Diagnostics Market, New Zealand, Category Contribution (%), 2010 19
3.5 In Vitro Diagnostics, New Zealand, Company share (2009-2010) 26
4 Clinical Chemistry In New Zealand 28
4.1 Clinical Chemistry, Market Segmentation 28
4.2 Clinical Chemistry Market, New Zealand, Revenue Mix ($m), 2010 29
4.3 Clinical Chemistry Market, New Zealand, Segment Contribution (%), 2010 30
4.4 Clinical Chemistry Overall Revenue (2003-2017) 31
4.4.1 Clinical Chemisty Analyzers Revenue (2003-2017) 35
4.4.2 Urine Analysis Revenue (2003-2017) 39
4.5 Clinical Chemistry Distribution Share (2009-2010) 43
4.6 Clinical Chemistry, New Zealand, Company share (2009-2010) 44
5 Genetic Testing In New Zealand 46
5.1 Genetic Testing, Market Segmentation 46
5.2 Genetic Testing Market, New Zealand, Revenue Mix ($m), 2010 47
5.3 Genetic Testing Market, New Zealand, Segment Contribution (%), 2010 48
5.4 Genetic Testing Overall Revenue (2003-2017) 49
5.5 Genetic Testing Distribution Share (2009-2010) 53
5.6 Genetic Testing, New Zealand, Company share (2009-2010) 54
6 Haematology In New Zealand 56
6.1 Haematology, Market Segmentation 56
6.2 Haematology Market, New Zealand, Revenue Mix ($m), 2010 57
6.3 Haematology Market, New Zealand, Segment Contribution (%), 2010 58
6.4 Haematology Overall Revenue (2003-2017) 59
6.4.1 Haematology Reagents Revenue (2003-2017) 63
6.4.2 Immunohaematology Revenue (2003-2017) 67
6.4.3 Haemostasis Revenue (2003-2017) 71
6.4.4 Haematology Rapid Tests Revenue (2003-2017) 75
6.4.5 Haematology Cell Counters Revenue (2003-2017) 79
6.5 Haematology Distribution Share (2009-2010) 83
6.6 Haematology, New Zealand, Company share (2009-2010) 84
7 Histology And Cytology In New Zealand 86
7.1 Histology and Cytology, Market Segmentation 86
7.2 Histology And Cytology Market, New Zealand, Revenue Mix ($m), 2010 87
7.3 Histology And Cytology Market, New Zealand, Segment Contribution (%), 2010 88
7.4 Histology And Cytology Overall Revenue (2003-2017) 89
7.5 Histology And Cytology Distribution Share (2009-2010) 93
7.6 Histology And Cytology, New Zealand, Company share (2009-2010) 94
8 Immuno Chemistry In New Zealand 96
8.1 Immuno Chemistry Market, New Zealand, Revenue Mix ($m), 2010 96
8.2 Immuno Chemistry Market, New Zealand, Segment Contribution (%), 2010 97
8.3 Immuno Chemistry Overall Revenue (2003-2017) 98
8.3.1 Disease Specific Immunochemistry Revenue (2003-2017) 102
8.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 106
8.3.3 Endocrinology Tests Revenue (2003-2017) 110
8.3.4 Therapeutic Drug Monitoring Revenue (2003-2017) 114
8.3.5 Immunochemistry Analyzers Revenue (2003-2017) 118
8.4 Immuno Chemistry Distribution Share (2009-2010) 122
8.5 Immuno Chemistry, New Zealand, Company share (2009-2010) 123
9 Infectious Immunology In New Zealand 125
9.1 Infectious Immunology, Market Segmentation 125
9.2 Infectious Immunology Market, New Zealand, Revenue Mix ($m), 2010 126
9.3 Infectious Immunology Market, New Zealand, Segment Contribution (%), 2010 127
9.4 Infectious Immunology Overall Revenue (2003-2017) 128
9.5 Infectious Immunology Distribution Share (2009-2010) 132
9.6 Infectious Immunology, New Zealand, Company share (2009-2010) 133
10 Microbiology Culture In New Zealand 135
10.1 Microbiology Culture, Market Segmentation 135
10.2 Microbiology Culture Market, New Zealand, Revenue Mix ($m), 2010 136
10.3 Microbiology Culture Market, New Zealand, Segment Contribution (%), 2010 137
10.4 Microbiology Culture Overall Revenue (2003-2017) 138
10.4.1 Microbiology Analyzers Revenue (2003-2017) 142
10.5 Microbiology Culture Distribution Share (2009-2010) 146
10.6 Microbiology Culture, New Zealand, Company share (2009-2010) 147
11 Overview of Key Companies in New Zealand In Vitro Diagnostics Market 149
11.1 F. Hoffmann-La Roche Ltd. 149
11.1.1 Company Overview 149
11.1.2 Share in the New Zealand In Vitro Diagnostics Market 149
11.2 Sysmex Corporation 150
11.2.1 Company Overview 150
11.2.2 Share in the New Zealand In Vitro Diagnostics Market 150
11.3 Abbott Laboratories 151
11.3.1 Company Overview 151
11.3.2 Share in the New Zealand In Vitro Diagnostics Market 151
11.4 Beckman Coulter, Inc. 152
11.4.1 Company Overview 152
11.4.2 Share in the New Zealand In Vitro Diagnostics Market 152
11.5 Siemens Healthcare 153
11.5.1 Company Overview 153
11.5.2 Share in the New Zealand In Vitro Diagnostics Market 153
11.6 Becton, Dickinson and Company 154
11.6.1 Company Overview 154
11.6.2 Share in the New Zealand In Vitro Diagnostics Market 154
11.7 Ortho-Clinical Diagnostics Inc. 155
11.7.1 Company Overview 155
11.8 Bio-Rad Laboratories, Inc. 155
11.8.1 Company Overview 155
11.9 bioMerieux S.A. 155
11.9.1 Company Overview 155
11.10 Alere Inc. 156
11.10.1 Company Overview 156
11.11 Qiagen N.V. 156
11.11.1 Company Overview 156
11.12 DiaSorin S.p.A 157
11.12.1 Company Overview 157
11.13 Life Technologies Corporation 157
11.13.1 Company Overview 157
11.14 HORIBA, Ltd. 158
11.14.1 Company Overview 158
11.15 Gen-Probe Incorporated 158
11.15.1 Company Overview 158
11.16 Danaher Corporation 159
11.16.1 Company Overview 159
11.17 Grifols, S.A. 159
11.17.1 Company Overview 159
11.18 Phadia AB 159
11.18.1 Company Overview 159
11.19 Thermo Fisher Scientific Inc. 160
11.19.1 Company Overview 160
11.20 DIAGNOSTICA STAGO, Inc. 160
11.20.1 Company Overview 160
11.21 PerkinElmer, Inc. 161
11.21.1 Company Overview 161
12 In Vitro Diagnostics Market Pipeline Products 162
12.1 Clinical Chemisty Market Pipeline Products 162
12.2 Immuno Chemistry Market Pipeline Products 165
12.3 Haematology Market Pipeline Products 168
12.4 Infectious Immunology Market Pipeline Products 170
12.5 Microbiology Culture Market Pipeline Products 173
12.6 Histology and Cytology Market Pipeline Products 174
12.7 Genetic Testing Market Pipeline Products 175
13 Appendix 178
13.1 Definitions of Markets Covered in the Report 179
13.1.1 In Vitro Diagnostics 179
13.2 Research Methodology 189
13.3 Secondary Research 189
13.4 Primary Research 190
13.5 Models 190
13.6 Forecasts 191
13.7 Expert Panels 191
13.8 GlobalData Consulting 191
13.9 Currency Conversion 192
13.10 Contact Us 192
13.11 Disclaimer 192
[Inhaltsverzeichnis ausblenden]

1.1 List of Tables
Table 1: In Vitro Diagnostics, New Zealand, Overall Revenue ($m), USD Actual, 2003-2017 17
Table 2: In Vitro Diagnostics Market, New Zealand, Category Contribution (%), 2010 19
Table 3: In Vitro Diagnostics, New Zealand, Cross-Category Analysis, 2003-2017 21
Table 4: In Vitro Diagnostics, New Zealand, Overall Revenue ($m), USD Actual, Historic, 2003-2010 23
Table 5: In Vitro Diagnostics, New Zealand, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 25
Table 6: In Vitro Diagnostics, New Zealand, Company share by Revenue ($m), USD Actual, 2009-2010 27
Table 7: Clinical Chemistry Market, New Zealand, Segment Contribution (%), 2010 30
Table 8: Clinical Chemistry, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 32
Table 9: Clinical Chemistry, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 34
Table 10: Clinical Chemisty Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 36
Table 11: Clinical Chemisty Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 38
Table 12: Urine Analysis, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 40
Table 13: Urine Analysis, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 42
Table 14: Clinical Chemistry, New Zealand, Distribution Share by Revenue ($m), USD Actual, 2009-2010 43
Table 15: Clinical Chemistry, New Zealand, Company share by Revenue ($m), USD Actual 2009-2010 45
Table 16: Genetic Testing Market, New Zealand, Segment Contribution (%), 2010 48
Table 17: Genetic Testing, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 50
Table 18: Genetic Testing, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 52
Table 19: Genetic Testing, New Zealand, Distribution Share by Revenue ($m), USD Actual, 2009-2010 53
Table 20: Genetic Testing, New Zealand, Company share by Revenue ($m), USD Actual 2009-2010 55
Table 21: Haematology Market, New Zealand, Segment Contribution (%), 2010 58
Table 22: Haematology, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 60
Table 23: Haematology, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 62
Table 24: Haematology Reagents, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 64
Table 25: Haematology Reagents, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 66
Table 26: Immunohaematology, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 68
Table 27: Immunohaematology, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 70
Table 28: Haemostasis, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 72
Table 29: Haemostasis, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 74
Table 30: Haematology Rapid Tests, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 76
Table 31: Haematology Rapid Tests, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 78
Table 32: Haematology Cell Counters, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 80
Table 33: Haematology Cell Counters, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 82
Table 34: Haematology, New Zealand, Distribution Share by Revenue ($m), USD Actual, 2009-2010 83
Table 35: Haematology, New Zealand, Company share by Revenue ($m), USD Actual 2009-2010 85
Table 36: Histology And Cytology Market, New Zealand, Segment Contribution (%), 2010 88
Table 37: Histology And Cytology, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 90
Table 38: Histology And Cytology, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 92
Table 39: Histology And Cytology, New Zealand, Distribution Share by Revenue ($m), USD Actual, 2009-2010 93
Table 40: Histology And Cytology, New Zealand, Company share by Revenue ($m), USD Actual 2009-2010 95
Table 41: Immuno Chemistry Market, New Zealand, Segment Contribution (%), 2010 97
Table 42: Immuno Chemistry, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 99
Table 43: Immuno Chemistry, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 101
Table 44: Disease Specific Immunochemistry, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 103
Table 45: Disease Specific Immunochemistry, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 105
Table 46: Drugs of Abuse / Toxicology, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 107
Table 47: Drugs of Abuse / Toxicology, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 109
Table 48: Endocrinology Tests, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 111
Table 49: Endocrinology Tests, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 113
Table 50: Therapeutic Drug Monitoring, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 115
Table 51: Therapeutic Drug Monitoring, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 117
Table 52: Immunochemistry Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 119
Table 53: Immunochemistry Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 121
Table 54: Immuno Chemistry, New Zealand, Distribution Share by Revenue ($m), USD Actual, 2009-2010 122
Table 55: Immuno Chemistry, New Zealand, Company share by Revenue ($m), USD Actual 2009-2010 124
Table 56: Infectious Immunology Market, New Zealand, Segment Contribution (%), 2010 127
Table 57: Infectious Immunology, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 129
Table 58: Infectious Immunology, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 131
Table 59: Infectious Immunology, New Zealand, Distribution Share by Revenue ($m), USD Actual, 2009-2010 132
Table 60: Infectious Immunology, New Zealand, Company share by Revenue ($m), USD Actual 2009-2010 134
Table 61: Microbiology Culture Market, New Zealand, Segment Contribution (%), 2010 137
Table 62: Microbiology Culture, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 139
Table 63: Microbiology Culture, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 141
Table 64: Microbiology Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 143
Table 65: Microbiology Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 145
Table 66: Microbiology Culture, New Zealand, Distribution Share by Revenue ($m), USD Actual, 2009-2010 146
Table 67: Microbiology Culture, New Zealand, Company share by Revenue ($m), USD Actual 2009-2010 148
Table 68: Clinical Chemisty Market Pipeline Products 162
Table 69: Immuno Chemistry Market Pipeline Products 165
Table 70: Haematology Market Pipeline Products 168
Table 71: Infectious Immunology Market Pipeline Products 170
Table 72: Microbiology Culture Market Pipeline Products 173
Table 73: Histology and Cytology Market Pipeline Products 174
Table 74: Genetic Testing Market Pipeline Products 175
Table 75: USD to Local Currency, New Zealand, Average Actual Rate 2003-2010 192
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 15
Figure 2: In Vitro Diagnostics, New Zealand, Overall Revenue ($m), USD Actual, 2003-2017 16
Figure 3: In Vitro Diagnostics Market, New Zealand, Revenue Mix ($m), 2010 18
Figure 4: In Vitro Diagnostics Market, New Zealand, Category Contribution (%), 2010 19
Figure 5: In Vitro Diagnostics, New Zealand, Cross-Category Analysis, 2003-2017 20
Figure 6: In Vitro Diagnostics, New Zealand, Overall Revenue ($m), USD Actual, Historic, 2003-2010 22
Figure 7: In Vitro Diagnostics, New Zealand, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 24
Figure 8: In Vitro Diagnostics, New Zealand, Company share (%), 2010 26
Figure 9: Clinical Chemistry, Market Segmentation 28
Figure 10: Clinical Chemistry Market, New Zealand, Revenue Mix ($m), 2010 29
Figure 11: Clinical Chemistry Market, New Zealand, Segment Contribution (%), 2010 30
Figure 12: Clinical Chemistry, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 31
Figure 13: Clinical Chemistry, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 33
Figure 14: Clinical Chemisty Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 35
Figure 15: Clinical Chemisty Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 37
Figure 16: Urine Analysis, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 39
Figure 17: Urine Analysis, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 41
Figure 18: Clinical Chemistry, New Zealand, Company share (%), 2010 44
Figure 19: Genetic Testing, Market Segmentation 46
Figure 20: Genetic Testing Market, New Zealand, Revenue Mix ($m), 2010 47
Figure 21: Genetic Testing Market, New Zealand, Segment Contribution (%), 2010 48
Figure 22: Genetic Testing, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 49
Figure 23: Genetic Testing, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 51
Figure 24: Genetic Testing, New Zealand, Company share (%), 2010 54
Figure 25: Haematology, Market Segmentation 56
Figure 26: Haematology Market, New Zealand, Revenue Mix ($m), 2010 57
Figure 27: Haematology Market, New Zealand, Segment Contribution (%), 2010 58
Figure 28: Haematology, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 59
Figure 29: Haematology, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 61
Figure 30: Haematology Reagents, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 63
Figure 31: Haematology Reagents, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 65
Figure 32: Immunohaematology, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 67
Figure 33: Immunohaematology, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 69
Figure 34: Haemostasis, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 71
Figure 35: Haemostasis, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 73
Figure 36: Haematology Rapid Tests, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 75
Figure 37: Haematology Rapid Tests, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 77
Figure 38: Haematology Cell Counters, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 79
Figure 39: Haematology Cell Counters, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 81
Figure 40: Haematology, New Zealand, Company share (%), 2010 84
Figure 41: Histology and Cytology, Market Segmentation 86
Figure 42: Histology And Cytology Market, New Zealand, Revenue Mix ($m), 2010 87
Figure 43: Histology And Cytology Market, New Zealand, Segment Contribution (%), 2010 88
Figure 44: Histology And Cytology, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 89
Figure 45: Histology And Cytology, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 91
Figure 46: Histology And Cytology, New Zealand, Company share (%), 2010 94
Figure 47: Immuno Chemistry Market, New Zealand, Revenue Mix ($m), 2010 96
Figure 48: Immuno Chemistry Market, New Zealand, Segment Contribution (%), 2010 97
Figure 49: Immuno Chemistry, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 98
Figure 50: Immuno Chemistry, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 100
Figure 51: Disease Specific Immunochemistry, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 102
Figure 52: Disease Specific Immunochemistry, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 104
Figure 53: Drugs of Abuse / Toxicology, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 106
Figure 54: Drugs of Abuse / Toxicology, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 108
Figure 55: Endocrinology Tests, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 110
Figure 56: Endocrinology Tests, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 112
Figure 57: Therapeutic Drug Monitoring, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 114
Figure 58: Therapeutic Drug Monitoring, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 116
Figure 59: Immunochemistry Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 118
Figure 60: Immunochemistry Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 120
Figure 61: Immuno Chemistry, New Zealand, Company share (%), 2010 123
Figure 62: Infectious Immunology, Market Segmentation 125
Figure 63: Infectious Immunology Market, New Zealand, Revenue Mix ($m), 2010 126
Figure 64: Infectious Immunology Market, New Zealand, Segment Contribution (%), 2010 127
Figure 65: Infectious Immunology, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 128
Figure 66: Infectious Immunology, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 130
Figure 67: Infectious Immunology, New Zealand, Company share (%), 2010 133
Figure 68: Microbiology Culture, Market Segmentation 135
Figure 69: Microbiology Culture Market, New Zealand, Revenue Mix ($m), 2010 136
Figure 70: Microbiology Culture Market, New Zealand, Segment Contribution (%), 2010 137
Figure 71: Microbiology Culture, New Zealand, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 138
Figure 72: Microbiology Culture, New Zealand, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 140
Figure 73: Microbiology Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 142
Figure 74: Microbiology Analyzers, New Zealand, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 144
Figure 75: Microbiology Culture, New Zealand, Company share (%), 2010 147
Figure 76: F. Hoffmann-La Roche Ltd., Company Share (%),New Zealand In Vitro Diagnostics Market, 2010 149
Figure 77: Sysmex Corporation, Company Share (%),New Zealand In Vitro Diagnostics Market, 2010 150
Figure 78: Abbott Laboratories, Company Share (%),New Zealand In Vitro Diagnostics Market, 2010 151
Figure 79: Beckman Coulter, Inc., Company Share (%),New Zealand In Vitro Diagnostics Market, 2010 152
Figure 80: Siemens Healthcare, Company Share (%),New Zealand In Vitro Diagnostics Market, 2010 153
Figure 81: Becton, Dickinson and Company, Company Share (%),New Zealand In Vitro Diagnostics Market, 2010 154
[Tabellenverzeichnis ausblenden]